-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk To Present 12 New Semaglutide And MASH Research Abstracts At AASLD’s The Liver Meeting 2026

Benzinga·10/28/2026 13:08:24
  • The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASH
  • New post hoc data from ESSENCE examines changes in liver related parameters with semaglutide 2.4 mg vs placebo in people with MASH and a BMI below 27 kg/m²
  • Four posters, including one oral presentation, on investigational efruxifermin research and new analyses from the phase 2b SYMMETRY trial in compensated MASH cirrhosis

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 28, 2026 /PRNewswire/ -- Novo Nordisk today announced that 12 new abstracts on semaglutide real-world and clinical data will be presented at the American Association for the Study of Liver Diseases congress, The Liver Meeting® 2026, from November 5-9 in Denver, Colorado.